دواعي استعمال براليونت 150مجم 2 قلم معبأ 1 مل

Alirocumab 150 mg/1 ml solution for subcutaneous injection in pre-filled pens (Praluent) by Sanofi; pack of 2 pens.

• Reduce risk of major adverse cardiovascular events in adults at increased riskDailyMed (US NLM)
• Adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolaemia, adults and children >=8 years with HeFH, and adults with HoFHDailyMed (US NLM)

• Common (>5% and more than placebo): injection site reactions and influenza (primary hypercholesterolaemia); myalgia (established CV disease).نشرة دولية لنفس التركيبة · DailyMed (US NLM)

• History of serious hypersensitivity reaction to alirocumab or any excipient.نشرة دولية لنفس التركيبة · DailyMed (US NLM)

• Hypersensitivity reactions including hypersensitivity vasculitis, angioedema and reactions requiring hospitalisation; discontinue if serious reactions occur.نشرة دولية لنفس التركيبة · DailyMed (US NLM)

• Human data insufficient to evaluate drug-associated risk; as an IgG antibody, alirocumab crosses the placenta, increasingly near term.نشرة دولية لنفس التركيبة · DailyMed (US NLM)
• No information on presence in human milk; weigh benefits of breastfeeding against clinical need.نشرة دولية لنفس التركيبة · DailyMed (US NLM)

• Assess LDL-C when clinically appropriate (effect measurable as early as 4 weeks); for 300 mg every 4 weeks measure LDL-C just before the next dose.نشرة دولية لنفس التركيبة · DailyMed (US NLM)